Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial
Juliet Mpendo, Gaudensia Mutua, Annet Nanvubya, Omu Anzala, Julien Nyombayire, Etienne Karita, Len Dally, Drew Hannaman, Matt Price, Patricia E Fast, Frances Priddy, Huub C Gelderblom, Nancy K Hills, Juliet Mpendo, Gaudensia Mutua, Annet Nanvubya, Omu Anzala, Julien Nyombayire, Etienne Karita, Len Dally, Drew Hannaman, Matt Price, Patricia E Fast, Frances Priddy, Huub C Gelderblom, Nancy K Hills
Abstract
Introduction: Intramuscular electroporation (IM/EP) is a vaccine delivery technique that improves the immunogenicity of DNA vaccines. We evaluated the acceptability and tolerability of electroporation among healthy African study participants.
Methods: Forty-five participants were administered a DNA vaccine (HIV-MAG) or placebo by electroporation at three visits occurring at four week-intervals. At the end of each visit, participants were asked to rate pain at four times: (1) when the device was placed on the skin and vaccine injected, before the electrical stimulation, (2) at the time of electrical stimulation and muscle contraction, and (3) at 10 minutes and (4) 30 minutes after the procedure was completed. For analyses, pain level was dichotomized as either "acceptable" (none/slight/uncomfortable) or "too much" (Intense, severe, and very severe) and examined over time using repeated measures models. Optional brief comments made by participants were summarized anecdotally.
Results: All 45 participants completed all three vaccination visits; none withdrew from the study due to the electroporation procedure. Most (76%) reported pain levels as acceptable at every time point across all vaccination visits. The majority of "unacceptable" pain was reported at the time of electrical stimulation. The majority of the participants (97%) commented that they preferred electroporation to standard injection.
Conclusion: Repeated intramuscular electroporation for vaccine delivery was found to be acceptable and feasible among healthy African HIV vaccine trial participants. The majority of participants reported an acceptable pain level at all vaccination time points. Further investigation may be warranted into the value of EP to improve immunization outcomes. ClinicalTrials.gov NCT01496989.
Conflict of interest statement
PEF, MP and FP were employees of IAVI at the time of the study. DH is an employee of Ichor Medical Sciences Inc which owns the rights to the TriGrid Delivery System. The rest of the authors have no competing interests.
Figures
References
- Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007;25(20):4085–92.
- Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV‐1 DNA candidate vaccine. The Journal of infectious diseases. 2006;194(12):1650–60.
- Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nature reviews Genetics. 2008;9(10):776–88.
- Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, Vittorino R, et al. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine. 2011;29(4):795–803.
- Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. The Journal of infectious diseases. 2013;208(5):818–29.
- Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PloS one. 2011;6(5):e19252.
- Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, et al. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. PloS one. 2015;10(8):e0134287.
- Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, et al. Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Molecular therapy Methods & clinical development. 2016;3:16061.
- Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, et al. Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers. Human vaccines & immunotherapeutics. 2013;9(10):2246–52.
- Szenborn L, Czajka H, Brzostek J, Konior R, Caubet M, Ulianov L, et al. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12–18 months of age. The Pediatric infectious disease journal. 2013;32(7):777–85.
- Van Herck K, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sexually transmitted infections. 2007;83(6):426–32.
- Hannan D. Gene Vaccines. 1 ed Josef Thalhamer RW, Scheiblofer Sandra, editor. New York: Springer-Verlag Wien; 2012. 330 p.
- Vittinghof E. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. Revised ed New York, USA: Spring-Verlag New York Inc; 2012. 14 March 2012.
- El-Kamary SS, Billington M, Deitz S, Colby E, Rhinehart H, Wu Y, et al. Safety and tolerability of the Easy Vax clinical epidermal electroporation system in healthy adults. Molecular therapy: the journal of the American Society of Gene Therapy. 2012;20(1):214–20.
- Wallace M, Evans B, Woods S, Mogg R, Zhang L, Finnefrock AC, et al. Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Molecular therapy: the journal of the American Society of Gene Therapy. 2009;17(5):922–8.
- Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Brave A, et al. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. PloS one. 2015;10(6):e0131748.
Source: PubMed